Final results of neoadjuvant trial of bevacizumab (B) and trastuzumab (T) in combination with weekly paclitaxel (P) as neoadjuvant treatment in HER2-positive breast cancer: A phase II trial (AVANTHER)

被引：0
|
作者：
Fernandez, M.
Calvo, I.
Martinez, N.
Herrero, M.
Quijano, Y.
Duran, H.
Garcia-Aranda, M.
Suarez, A.
-Rios, F. Lopez
Perez, D.
Perea, S.
Hidalgo, M.
Garcia-Estevez, L.
机构：
[1] Ctr Integral Oncol Clara Campal, Madrid, Spain
[2] Hosp Ramon & Cajal, E-28034 Madrid, Spain
[3] Hosp Costa del Sol, Marbella, Spain
来源：
CANCER RESEARCH | 2012年 / 72卷
关键词：
D O I：
10.1158/0008-5472.SABCS12-P1-14-10
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1-14-10
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Surgical aspect in NOAH Phase III trial (neoadjuvant trastuzumab in HER2-positive locally advanced breast cancer)
    Semiglazov, V.
    Eiermann, W.
    Manikhas, A.
    Bozok, A.
    Lluch, A.
    Tjulandine, S.
    Feyereislova, A.
    Valagussae, P.
    Baselga, J.
    Gianni, L.
    EJC SUPPLEMENTS, 2008, 6 (07): : 169 - 170
  • [22] Combination of pyrotinib with trastuzumab, taxanes and platinum as neoadjuvant therapy in patients with HER2-positive early or locally advanced breast cancer: a multicenter phase II trial
    Zhou, Hao
    Wang, Lei
    Wang, Lei
    Guo, Zhaoji
    CANCER RESEARCH, 2023, 83 (05)
  • [23] Weekly paclitaxel, trastuzumab, carboplatin is a highly effective neoadjuvant regimen in HER2-positive breast cancer: Results from the TRAIN-study
    van Ramshorst, M. S.
    van Werkhoven, E.
    Mandjes, I. A. M.
    Schot, M.
    Wesseling, J.
    Peeters, M-JTFD Vrancken
    Rodenhuis, S.
    Oosterkamp, H. M.
    Bos, M. E. M.
    Terwogt, J. M. Meerum
    Linn, S. C.
    Sonke, G. S.
    CANCER RESEARCH, 2016, 76
  • [24] Translational Results of Zo-NAnTax: A Phase II Trial of Neoadjuvant Zoledronic Acid in HER2-Positive Breast Cancer
    Crocamo, Susanne
    Binato, Renata
    dos Santos, Everton Cruz
    de Paula, Bruno
    Abdelhay, Eliana
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (24)
  • [25] A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study)
    Patel, Tejal A.
    Ensor, Joe E.
    Creamer, Sarah L.
    Boone, Toniva
    Rodriguez, Angel A.
    Niravath, Poly A.
    Darcourt, Jorge G.
    Meisel, Jane L.
    Li, Xiaoxian
    Zhao, Jing
    Kuhn, John G.
    Rosato, Roberto R.
    Qian, Wei
    Belcheva, Anna
    Schwartz, Mary R.
    Kaklamani, Virginia G.
    Chang, Jenny C.
    BREAST CANCER RESEARCH, 2019, 21 (01)
  • [26] A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study)
    Tejal A. Patel
    Joe E. Ensor
    Sarah L. Creamer
    Toniva Boone
    Angel A. Rodriguez
    Poly A. Niravath
    Jorge G. Darcourt
    Jane L. Meisel
    Xiaoxian Li
    Jing Zhao
    John G. Kuhn
    Roberto R. Rosato
    Wei Qian
    Anna Belcheva
    Mary R. Schwartz
    Virginia G. Kaklamani
    Jenny C. Chang
    Breast Cancer Research, 21
  • [27] Phase II randomized trial of neoadjuvant trastuzumab and pertuzumab with either palbociclib plus letrozole or paclitaxel for postmenopausal women with estrogen receptor-positive/HER2-positive breast cancer - The TOUCH trial
    Biganzoli, Laura
    Brain, Etienne
    Malorni, Luca
    Gombos, Andrea
    Hasler-Strub, Ursula
    Zamagni, Claudio
    Chakiba, Camille
    Roschitzki-Voser, Heidi
    Regan, Meredith M.
    CANCER RESEARCH, 2021, 81 (04)
  • [28] Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer
    Baselga, J.
    Manikhas, A.
    Cortes, J.
    Llombart, A.
    Roman, L.
    Semiglazov, V. F.
    Byakhov, M.
    Lokanatha, D.
    Forenza, S.
    Goldfarb, R. H.
    Matera, J.
    Azarnia, N.
    Hudis, C. A.
    Rozencweig, M.
    ANNALS OF ONCOLOGY, 2014, 25 (03) : 592 - 598
  • [29] Phase II Study of Neoadjuvant Weekly nab-Paclitaxel and Carboplatin, With Bevacizumab and Trastuzumab, As Treatment For Women With Locally Advanced HER2+ Breast Cancer
    Yardley, Denise A.
    Raefsky, Eric
    Castillo, Raul
    Lahiry, Anup
    LoCicero, Richard
    Thompson, Dana
    Shastry, Mythili
    Burris, Howard A., III
    Hainsworth, John D.
    CLINICAL BREAST CANCER, 2011, 11 (05) : 297 - 305
  • [30] Final results of a phase 2 trial using a novel, non-anthracycline neoadjuvant chemotherapy regimen in Her2-positive breast cancer
    O'Regan, Ruth M.
    Gabram, Sheryl
    Styblo, Toncred
    Rizzo, Monica
    Wood, William
    Srinivasiah, Jayanthi
    Jonas, William
    Schnell, Fred
    Adams, Amy
    Nahta, Rita
    Zelnak, Amelia
    CANCER RESEARCH, 2012, 72
12345